Search research articles
Contact Us
Filters
Showing results (121-130 of 420) with videos related to
Page
of 42
Sort By:
Diagnostic Microbiology and Infectious Disease
|
March 15, 2006
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)
Kelley A Fedler, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
February 26, 2013
Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample
Ronald N Jones, Amy A Watters, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
October 14, 2009
Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots
Gary J Moet, Amy A Watters, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
February 5, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
February 5, 2014
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
January 8, 2008
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus
Thomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
November 14, 2012
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)
David J Farrell, Robert K Flamm, Ronald N Jones, et al.
Diagnostic Microbiology and Infectious Disease
|
January 22, 2014
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011)
Michael A Pfaller, Robert K Flamm, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
January 14, 2014
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types
David J Farrell, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
September 27, 2012
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)
Ronald N Jones, Helio S Sader, Rodrigo E Mendes, et al.
Page
of 42
Search research articles
Search
Showing results (121-130 of 420) with videos related to
Sort By:
Page
of 42
Diagnostic Microbiology and Infectious Disease
|
March 15, 2006
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)
Kelley A Fedler, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
February 26, 2013
Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample
Ronald N Jones, Amy A Watters, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
October 14, 2009
Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots
Gary J Moet, Amy A Watters, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
February 5, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
February 5, 2014
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
January 8, 2008
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus
Thomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
November 14, 2012
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)
David J Farrell, Robert K Flamm, Ronald N Jones, et al.
Diagnostic Microbiology and Infectious Disease
|
January 22, 2014
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011)
Michael A Pfaller, Robert K Flamm, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
January 14, 2014
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types
David J Farrell, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
September 27, 2012
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)
Ronald N Jones, Helio S Sader, Rodrigo E Mendes, et al.
Page
of 42